Insights

Research insights, forthcoming.

Short, sourced analysis of the developments that matter in China’s pharmaceutical industry — drawn from our reports and the primary data behind them.

Coming soon

We publish when the research is ready.

Insights is where we will publish commentary between report editions: regulatory decisions, approval milestones, licensing transactions and payment reform — each traced to the primary source it came from. The first pieces are in preparation.

01

Regulatory & approvals

What the NMPA decided, what it means for the pipeline, and which approval records support the reading.

02

Market access & payment

NRDL negotiation outcomes, procurement rules and the pricing dynamics that follow from them.

03

Deals & policy

License-out transactions, NewCo structures and the industrial policy shaping cross-border activity.

Be first to know

Subscribers hear first.

New insights and new report releases are announced to subscribers before they appear anywhere else. Join the list and we will write to you when the first issue is published.

No spam. Unsubscribe anytime. Report releases and research insights only. See our Privacy Policy.

In the meantime

The research is already available.

Our 2025 flagship archive is published and available now. A dedicated cardiovascular report is in production.